Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II.
Rocha JF, Ebersbach G, Lees A, Tolosa E, Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Magalhães D, Gama H, Soares-da-Silva P. Rocha JF, et al. Among authors: magalhaes d. Front Neurol. 2021 Nov 5;12:754016. doi: 10.3389/fneur.2021.754016. eCollection 2021. Front Neurol. 2021. PMID: 34803891 Free PMC article.
Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
Chaudhuri KR, Odin P, Ferreira JJ, Antonini A, Rascol O, Kurtis MM, Storch A, Bannister K, Soares-da-Silva P, Costa R, Magalhães D, Rocha JF. Chaudhuri KR, et al. Among authors: magalhaes d. BMC Neurol. 2022 Mar 12;22(1):88. doi: 10.1186/s12883-022-02602-8. BMC Neurol. 2022. PMID: 35279112 Free PMC article. Clinical Trial.
The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II.
Rocha JF, Ebersbach G, Lees A, Tolosa E, Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Magalhães D, Gama H, Soares-da-Silva P. Rocha JF, et al. Among authors: magalhaes d. Front Neurol. 2022 Aug 23;13:994114. doi: 10.3389/fneur.2022.994114. eCollection 2022. Front Neurol. 2022. PMID: 36081875 Free PMC article.
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years.
Magro F, Magalhães D, Patita M, Arroja B, Lago P, Rosa I, Tavares de Sousa H, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Santiago M, Dias S, Alves C, Afonso J, Danese S, Peyrin-Biroulet L, Dias CC; GEDII. Magro F, et al. Among authors: magalhaes d. Clin Gastroenterol Hepatol. 2022 Sep;20(9):2059-2073.e7. doi: 10.1016/j.cgh.2021.12.004. Epub 2021 Dec 9. Clin Gastroenterol Hepatol. 2022. PMID: 34896644
Role of epithelial ion transports in inflammatory bowel disease.
Magalhães D, Cabral JM, Soares-da-Silva P, Magro F. Magalhães D, et al. Am J Physiol Gastrointest Liver Physiol. 2016 Apr 1;310(7):G460-76. doi: 10.1152/ajpgi.00369.2015. Epub 2016 Jan 7. Am J Physiol Gastrointest Liver Physiol. 2016. PMID: 26744474 Free article. Review.
Amine neurotransmitters, inflammation and epithelial sodium transport.
Soares-da-Silva P, Cabral JM, Magalhães D, Fraga S, Magro F. Soares-da-Silva P, et al. Among authors: magalhaes d. Exp Physiol. 2016 Apr;101(4):459-64. doi: 10.1113/EP085284. Epub 2015 Dec 14. Exp Physiol. 2016. PMID: 26548358 Free article. Review.
227 results